Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report), TELA Bio (TELA – Research Report) and AngioDynamics (ANGO – Research Report) with bullish sentiments.

Prime Medicine, Inc. (PRME)

In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Prime Medicine, Inc., with a price target of $19.00. The company’s shares closed last Thursday at $3.41, close to its 52-week low of $3.28.

According to TipRanks.com, Biliouris is ranked 0 out of 5 stars with an average return of -5.0% and a 35.3% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Prime Medicine, Inc. with a $13.00 average price target, a 279.0% upside from current levels. In a report issued on October 2, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TELA Bio (TELA)

In a report released yesterday, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on TELA Bio, with a price target of $12.00. The company’s shares closed last Thursday at $2.52, close to its 52-week low of $2.32.

According to TipRanks.com, Cronin is a 1-star analyst with an average return of -2.0% and a 40.5% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.

Currently, the analyst consensus on TELA Bio is a Strong Buy with an average price target of $10.00.

AngioDynamics (ANGO)

In a report released yesterday, John Young CFA from Canaccord Genuity maintained a Buy rating on AngioDynamics, with a price target of $12.00. The company’s shares closed last Thursday at $6.37.

According to TipRanks.com, CFA is a 2-star analyst with an average return of 0.4% and a 50.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Staar Surgical, and Pulmonx.

AngioDynamics has an analyst consensus of Strong Buy, with a price target consensus of $13.00, implying an 88.4% upside from current levels. In a report issued on September 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.

Read More on PRME:

• Stellantis cuts 2024 targets, TPG acquires AT&T’s DirecTV stake: Morning Buzz
• Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley
• Prime Medicine pact with Bristol doesn’t change thesis, says Stifel
• Morning Movers: Stellantis skids following FY24 guidance cut
• Prime Medicine Strikes $3.5B Deal for T-Cell Therapy Advances